All Stories

  1. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

    Article • ClinicoEconomics and Outcomes Research, November 2019, Taylor & Francis

    MURTUZA Bharmal

  2. Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

    Article • ClinicoEconomics and Outcomes Research, May 2019, Dove Medical Press

    MURTUZA Bharmal

  3. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States

    Article • Journal of Medical Economics, September 2018, Taylor & Francis

    MURTUZA Bharmal, Emmanuelle Boutmy

  4. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights

    Article • Journal of Comparative Effectiveness Research, September 2018, Future Medicine

    MURTUZA Bharmal

  5. Quality of life with Merkel Cell Carcinoma

    Article • Future Oncology, December 2017, Future Medicine

    MURTUZA Bharmal